Jacob Pontoppidan Thyssen

Jacob Pontoppidan Thyssen

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Jacob Pontoppidan Thyssen

Department of Dermato‐Venereology & Wound Healing Centre Copenhagen University Hospital, Bispebjerg and Frederiksberg Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2015 in Contact Dermatitis
Verified
Journal Article
Open access
PDF file
JJJeanne D. Johansen
Jeanne D. Johansen
KAKristiina Aalto‐Korte
Kristiina Aalto‐Korte
TATove Agner
Tove Agner
KAKlaus E. Andersen
Klaus E. Andersen
ABAndreas Bircher
Andreas Bircher
Wolfgang UterWolfgang Uter
Wolfgang Uter
Summary: The present guideline summarizes all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions and discussions of different pertinent topics are followed by a highlighted short practical recommendation. Topics comprise, after an introduction with important definitions, materials, technique, modifications of epicutaneous testing, individual factors influencing the patch test outcome or necessitating special considerations, children, patients with occupational contact dermatitis and drug eruptions as special groups, patch testing of materials brought in by the patient, adverse effects of patch testing, and the final evaluation and patient counselling based on this judgement. Finally, short reference is made to aspects of (continuing) medical education and to electronic collection of data for epidemiological surveillance.

21 August 2007 in Contact Dermatitis
Verified
Journal Article
Open access
PDF file
JTJacob Pontoppidan Thyssen
Jacob Pontoppidan Thyssen
Allan LinnebergAllan Linneberg
Allan Linneberg
TMTorkil Menné
Torkil Menné
JJJeanne Duus Johansen
Jeanne Duus Johansen
A substantial number of studies have investigated the prevalence of contact allergy in the general population and in unselected subgroups of the general population. The aim of this review was to determine a median prevalence and summarize the main findings from studies on contact allergy in the general population. Published research mainly originates from North America and Western Europe. The median prevalence of contact allergy to at least 1 allergen was 21.2% (range 12.5–40.6%), and the weighted average prevalence was 19.5%, based on data collected on all age groups and all countries between 1966 and 2007. The most prevalent contact allergens were nickel, thimerosal, and fragrance mix. The median nickel allergy prevalence was 8.6% (range 0.7–27.8%) and demonstrates that nickel was an important cause of contact allergy in the general population and that it was widespread in both men and women. Numerous studies demonstrated that pierced ears were a significant risk factor for nickel allergy. Nickel was a risk factor for hand eczema in women. Finally, heavy smoking was associated with contact allergy, mostly in women. Population‐based epidemiological studies are considered a prerequisite in the surveillance of national and international contact allergy epidemics.

17 November 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
AWAndreas Wollenberg
Andreas Wollenberg
SCS. Christen‐Zäch
S. Christen‐Zäch
ATalain taieb
alain taieb
CPC. Paul
C. Paul
JTJ.P. Thyssen
J.P. Thyssen
FFFor The European Task Force On Atopic Dermatitis/Eadv Eczema Task Force
For The European Task Force On Atopic Dermatitis/Eadv Eczema Task Force
Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and pathogenic variabilities, the patient’s age and also target flare prevention. Basic therapy includes hydrating and barrier‐stabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible skin lesions are treated with anti‐inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid‐potency corticosteroids are proven agents for proactive therapy, which is defined as the long‐term intermittent anti‐inflammatory therapy of frequently relapsing skin areas. Systemic anti‐inflammatory or immunosuppressive treatment is a rapidly changing field requiring monitoring. Oral corticosteroids have a largely unfavourable benefit–risk ratio. The IL‐4R‐blocker dupilumab is a safe, effective and licensed, but expensive, treatment option with potential ocular side‐effects. Other biologicals targeting key pathways in the atopic immune response, as well as different Janus kinase inhibitors, are among emerging treatment options. Dysbalanced microbial colonization and infection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R‐blockers) only have limited effects on AD‐related itch and eczema lesions. Adjuvant therapy includes UV irradiation, preferably narrowband UVB or UVA1. Coal tar may be useful for atopic hand and foot eczema. Dietary recommendations should be patient‐specific, and elimination diets should only be advised in case of proven food allergy. Allergen‐specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress‐induced exacerbations. Efficacy‐proven 'Eczema school' educational programmes and therapeutic patient education are recommended for both children and adults.

29 January 2010 in Contact Dermatitis
Verified
Journal Article
Open access
PDF file
JTJacob P. Thyssen
Jacob P. Thyssen
JJJeanne D. Johansen
Jeanne D. Johansen
Allan LinnebergAllan Linneberg
Allan Linneberg
TMTorkil Menné
Torkil Menné
Numerous studies have investigated the prevalence and risk factors of hand eczema in the general population. These studies are of high value as they tend to be less biased than studies using clinical populations and as they are important for healthcare decision makers when they allocate resources. This study aimed to review the epidemiology of hand eczema in the general population.Literature was examined using Pubmed‐Medline, Biosis, Science Citation Index, and dermatology text books. On the basis of studies performed between 1964 and 2007, the point prevalence of hand eczema was around 4%, the 1‐year prevalence nearly 10%, whereas the lifetime prevalence reached 15%. Based on seven studies, the median incidence rate of hand eczema was 5.5 cases/1000 person‐years (women = 9.6 and men = 4.0). A high incidence rate was associated with female sex, contact allergy, atopic dermatitis, and wet work. Atopic dermatitis was the single most important risk factor for hand eczema. Hand eczema resulted in medical consultations in 70%, sick leave (> 7 days) in about 20%, and job change in about 10%. Mean sick time was longer among those with allergic hand eczema than those with atopic and irritant hand eczema. Moderate to severe extension of hand eczema was the strongest risk factor for persistence of hand eczema. Other risk factors included early onset of hand eczema and childhood eczema. The aetiology of hand eczema is multifactorial and includes environmental as well as genetic factors. Future studies should focus on unresolved areas of hand eczema, for example, genetic predisposition.

1 October 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JTJacob P. Thyssen
Jacob P. Thyssen
SKSanja Kezic
Sanja Kezic

31 May 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
LGL. Gether
L. Gether
LOL. K. Overgaard
L. K. Overgaard
AEA. Egeberg
A. Egeberg
JTJ. P. Thyssen
J. P. Thyssen